Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib maintenance in sBRCA/HRR mutated ovarian cancer
NCT02392676Phase 3Withdrawn
- Sponsor
- AstraZeneca
- Start
- Jul 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of olaparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by AstraZeneca. Planned start Jul 2016; status: withdrawn.
02
Drugs
olaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02392676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392676.